NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel; Clinical Assay Development Program (CADP).

Date: July 31, 2012.

Time: 8 a.m.–3 p.m.

Agenda: To review grant applications for the CADP.

Place: National Cancer Institute, NIH, Executive Plaza North, 6130 Executive Boulevard, Room J, Rockville, MD 20852.

Contact Person: Tracy G. Lively, Ph.D., Executive Secretary, Cancer Diagnosis Program (CADP), National Cancer Institute, NIH, 6130 Executive Boulevard, EPN/6035A, Bethesda, MD 20892, 301–496–9639, livelyt@mail.nih.gov.

Information is also available on the Institute’s Center’s home page: http://deainfo.nci.nih.gov/advisory/irg/irg.htm, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)


Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2012–10083 Filed 4–25–12; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Initial Review Group; Subcommittee I—Cancer Development.

Date: June 12–13, 2012.

Time: 8 a.m. to 1 p.m.

Agenda: To review and evaluate grant applications.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Sergei Radaev, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Blvd., Room 8113, Bethesda, MD 20892, 301–435–5655, sradaev@mail.nih.gov.

Information is also available on the Institute’s Center’s home page: http://deainfo.nci.nih.gov/advisory/irg/irg.htm, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)


Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2012–10082 Filed 4–25–12; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Aging; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Aging Initial Review Group; Biological Aging Review Committee.

Date: June 6–7, 2012.

Time: 3 p.m. to 12 p.m.

Agenda: To review and evaluate grant applications.

Place: Marina del Rey Hotel, 13534 Bali Way, Marina del Rey, CA 90292.

Contact Person: Jeanette L. Johnson, Ph.D., Scientific Review Officer, National Institutes on Aging, National Institutes of Health, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, 301–402–7705, johnsonj@nia.nih.gov.

Name of Committee: National Institute on Aging Initial Review Group; Biological Aging Review Committee.

Date: June 6–7, 2012.

Time: 3 p.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: Marina del Rey Hotel, 13534 Bali Way, Marina del Rey, CA 90292.

Contact Person: Bita Nakhai, Ph.D., Scientific Review Branch, National Institute on Aging, Gateway Building, 2C212, 7201 Wisconsin Avenue, Bethesda, MD 20814, 301–402–7701, nakhai@nia.nih.gov.

Name of Committee: National Institute on Aging Initial Review Group; Clinical Aging Review Committee.

Date: June 7–8, 2012.

Time: 12 p.m. to 11 a.m.

Agenda: To review and evaluate grant applications.

Place: Marina del Rey Hotel, 13534 Bali Way, Marina del Rey, CA 90292.

Contact Person: Alicia L. Markowska, Ph.D., DSC, National Institute on Aging, National Institutes of Health, Gateway Building, 2C212, 7201 Wisconsin Avenue, Bethesda, MD 20892, 301–496–9666, markowsa@nia.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)


Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2012–10081 Filed 4–25–12; 8:45 am]

BILLING CODE 4140–01–P
concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Cancer Institute Special Emphasis Panel; SBIR Topic 255 Development of Anticancer Agents

**Meeting I.**

**Date:** May 14, 2012.

**Time:** 12 p.m. to 3 p.m.

**Place:** National Institutes of Health, 6116 Executive Boulevard, Room 611, Rockville, MD 20852, (Telephone Conference Call).

**Contact Person:** Shakeel Ahmad, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Boulevard, Room 8139, Bethesda, MD 20892–8328, (301) 594–0114, ahmadss@mail.nih.gov.

**Name of Committee:** National Cancer Institute Special Emphasis Panel; SBIR Topic 255 Development of Anticancer Agents

**Meeting II.**

**Date:** May 15, 2012.

**Time:** 12 p.m. to 3 p.m.

**Place:** National Institutes of Health, 6116 Executive Boulevard, Room 210, Rockville, MD 20852, (Telephone Conference Call).

**Contact Person:** Virginia P. Wray, Ph.D., Deputy Chief, Research Programs Review Branch, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Blvd., Room 8125, Bethesda, MD 20892–8328, 301–496–9236, wrayv@mail.nih.gov.

**Name of Committee:** National Cancer Institute Special Emphasis Panel; SPORE in Breast, Prostate and Thyroid Cancers

**Date:** May 23–24, 2012.

**Time:** 8 a.m. to 1 p.m.

**Place:** Bethesda North Marriott Hotel & Conference Center, Montgomery County Conference Center Facility, 5701 Marinelli Road, North Bethesda, MD 20852.

**Contact Person:** Wlodek Lopaczynski, MD, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Blvd., Room 8131, Bethesda, MD 20892, 301–594–1402, lopacw@mail.nih.gov.

**Name of Committee:** National Cancer Institute Special Emphasis Panel; NCI Program Project Review Panel Meeting IV

**Date:** June 13–12, 2012.

**Time:** 3 p.m. to 6 p.m.

**Place:** Bethesda North Marriott Hotel & Conference Center Facility, Montgomery County Conference Center Facility, 5701 Marinelli Road, North Bethesda, MD 20852.

**Contact Person:** Majed M. Hamawy, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Boulevard, Room 8135, Bethesda, MD 20892, 301–594–6569, mhamawy@nih.gov.

**Name of Committee:** National Cancer Institute Special Emphasis Panel; NCI Program Project Review Panel Meeting II

**Date:** June 13–14, 2012.

**Time:** 8 a.m. to 1 p.m.

**Place:** DoubleTree Hotel Bethesda, (Formerly Holiday Inn Select), 8120 Wisconsin Avenue, Bethesda, MD 20814.

**Contact Person:** Delia Tang, MD, Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Blvd., Room 8123, Bethesda, MD 20892, 301–496–2330, tangdl@mail.nih.gov.

**Name of Committee:** National Cancer Institute Special Emphasis Panel; NCI Program Project Review Panel Meeting I

**Date:** June 14–15, 2012.

**Time:** 8 a.m. to 11 a.m.

**Place:** DoubleTree Hotel and Executive Meeting Center; 8120 Wisconsin Ave., Bethesda, MD 20814.

**Contact Person:** David G. Ransom, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Blvd., Room 8133, Bethesda, MD 20892–8328, 301–451–4757, david.ransom@nih.gov.

**Name of Committee:** National Cancer Institute Special Emphasis Panel; Small Grants Program for Cancer Epidemiology

**Date:** June 21–22, 2012.

**Time:** 8:30 a.m. to 5:30 p.m.

**Place:** Hilton Washington/Rockville, 1750 Rockville Pike, Rockville, MD 20852.

**Contact Person:** Joyce C. Pegues, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, NIH National Cancer Institute, NIH, 6116 Executive Boulevard, Room 7149, Bethesda, MD 20892–8329, 301–594–1286, peguesj@mail.nih.gov.

Information is also available on the Institute’s/Center’s home page: [http://deinfo.ncti.nih.gov/advisory/sep/sep.htm](http://deinfo.ncti.nih.gov/advisory/sep/sep.htm), where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

**Dated:** April 19, 2012.

**Jennifer S. Spaeth,**

**Director, Office of Federal Advisory Committee Policy.**

[FR Doc. 2012–10079 Filed 4–25–12; 8:45 am]

**BILLING CODE 4140–01–P**

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Mental Health; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Mental Health Special Emphasis Panel; Fast Fail—Experimental Medicines Contracts—Mood and Anxiety Disorders

**Date:** May 22, 2012.

**Time:** 1 p.m. to 6 p.m.

**Place:** National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

**Contact Person:** David I. Sommers, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, National Institutes of Health, 6001 Executive Blvd., Room 6154, MSC 9606, Bethesda, MD 20892–9606, 301–443–7861, dsommers@mail.nih.gov.

**Name of Committee:** National Institute of Mental Health Special Emphasis Panel; Fast Fail—Experimental Medicines Contracts—Autism

**Date:** May 24, 2012.

**Time:** 1 p.m. to 6 p.m.

**Place:** National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

**Contact Person:** David I. Sommers, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, National Institutes of Health, 6001 Executive Blvd., Room 6154, MSC 9606, Bethesda, MD 20892–9606, 301–443–7861, dsommers@mail.nih.gov.

**Name of Committee:** National Institute of Mental Health Special Emphasis Panel

**Date:** May 22, 2012.

**Time:** 1 p.m. to 6 p.m.

**Place:** National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

**Contact Person:** David I. Sommers, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, National Institutes of Health, 6001 Executive Blvd., Room 6154, MSC 9606, Bethesda, MD 20892–9606, 301–443–7861, dsommers@mail.nih.gov.

**Name of Committee:** National Institute of Mental Health Special Emphasis Panel; Fast Fail—Experimental Medicines Contracts—Psychotic Spectrum

**Date:** May 25, 2012.

**Time:** 1 p.m. to 6 p.m.

**Place:** National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

**Contact Person:** David I. Sommers, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, National Institutes of Health, 6001 Executive Blvd., Room 6154, MSC 9606, Bethesda, MD 20892–9606, 301–443–7861, dsommers@mail.nih.gov.